Spots Global Cancer Trial Database for A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Official Title: A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib
Study ID: NCT01735968
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine a maximum tolerated dose and/or recommended phase 2 dose of a combination of imatinib and BYL719 in the treatment of 3rd line GIST patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Oregon Health and Science University Dept. of OHSU (3), Portland, Oregon, United States
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Bordeaux, , France
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Bologna, BO, Italy
Novartis Investigative Site, Candiolo, TO, Italy
Novartis Investigative Site, Groningen, , Netherlands
Novartis Investigative Site, Leiden, , Netherlands
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Leeds, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
